 |
|
Major genetic breakthrough for ankylosing spondylitis brings treatment hope
October 22, 2007Research funded by the Wellcome Trust and the Arthritis Research Campaign has identified two genes implicated in the disease ankylosing spondylitis, a common disease primarily causing back pain and progressive stiffness. The research, published online today in Nature Genetics, suggests that a treatment currently being trialled for Crohn's disease may also be applied to this disease.
Ankylosing spondylitis affects as many as 1 in 200 men and 1 in 500 women in the UK, typically striking people in their late teens and twenties. Whilst it mainly affects the spine, it can also affect other joints, tendons and ligaments. More rarely, it can affect other areas, such as the eyes, lungs, bowel and heart.† High-profile sufferers of the condition include former England cricket captain Mike Atherton.
Now, using a technique known as genome-wide association scanning, researchers led by Professors Lon Cardon, Matthew Brown and Paul Wordsworth, from the Wellcome Trust Centre for Human Genetics at the University of Oxford have analysed DNA samples from 1,000 patients with ankylosing spondylitis and a further 1,500 people unaffected by the disease in search of genetic mutations which, if present, increase a person's risk of developing the disease. The findings from this study were then confirmed by a team at University of Texas (Houston) led by Professor John Reveille.
"Ankylosing spondylitis is a painful and often very disabling disease," says Professor Brown. "Yet, our understanding of the causes of the disease, and hence our ability to treat it effectively, is relatively poor."
The researchers have identified two genes, ARTS1 and IL23R, which increase the risk of developing the disease. Together with the genetic variant HLA-B27, this takes the number of genes definitely known to be involved in the disease to three. A person carrying all three variants would be expected to have a one in four chance of developing the disease.
The IL23R gene plays a role in the immune response to infection, providing instructions for making a receptor present on the surface of several types of immune system cells. The receptor is involved in triggering certain chemical signals inside the cell that promote inflammation and help coordinate the immune system's response to infection. It is already recognised as playing a role in a number of autoimmune diseases, such as Crohn's disease (a type of inflammatory bowel disease) and psoriasis (a skin disease). Ankylosing spondylitis, Crohn's disease and psoriasis are known to often occur together, and this genetic finding goes a long way to explain why.
Professor Brown believes that the unexpected involvement of IL23R in ankylosing spondylitis provides a major step towards being able to treat the disease.
"We already know that IL23R is involved in inflammation, but no one had ever thought it was involved in ankylosing spondylitis," says Professor Brown. "A treatment for Crohn's disease that inhibits the activity of this gene is already undergoing human trials. This looks very promising as a potential treatment for ankylosing spondylitis."
Scientists have known that there is a genetic component to ankylosing spondylitis for 37 years, since the discovery of the gene HLA-B27. However, how this gene led to disease is not known. Professor Brown believes that the gene ARTS1 may hold the answer.
A protein created by the HLA-B27 gene takes fragments of pathogens and displays them on the outside of immune cells. These fragments then trigger the immune system to fight against the pathogen. ARTS1 is involved in breaking up the pathogen into "bite-size chunks" that can be displayed by HLA-B27.
"This strongly suggests that in ankylosing spondylitis, there are problems with the information that the HLA-B27 protein receives, thereby causing the disease," says Professor Brown.
Scientists believe that ankylosing spondylitis may be triggered in genetically-susceptible people by bacteria commonly found in the gut. Why this should be the case is unclear, but it is hoped that the new genetic discoveries will help answer this question.
"These findings are very exciting and show the value of exploring the genetics of disease," says Dr Mark Walport, Director of the Wellcome Trust. "It usually takes many years between genetic discoveries and new treatments for disease. In this case the two genes discovered to be associated with ankylosing spondylitis provide striking insights into the mechanisms of the disease and offer a possible new pathway for treatment."
The study is a collaboration between the Wellcome Trust Case Control Consortium and the Australo-Anglo-American Spondylitis Consortium funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
"These genetic studies involve large patient samples and require expertise over a wide range of scientific specialities", says Professor Cardon. "Bringing together these two consortia was the final key that enabled these exciting discoveries."
Wellcome Trust
"Ankylosing spondylitis is a painful and often very disabling disease," says Professor Brown. "Yet, our understanding of the causes of the disease, and hence our ability to treat it effectively, is relatively poor."
The researchers have identified two genes, ARTS1 and IL23R, which increase the risk of developing the disease. Together with the genetic variant HLA-B27, this takes the number of genes definitely known to be involved in the disease to three. A person carrying all three variants would be expected to have a one in four chance of developing the disease.
The IL23R gene plays a role in the immune response to infection, providing instructions for making a receptor present on the surface of several types of immune system cells. The receptor is involved in triggering certain chemical signals inside the cell that promote inflammation and help coordinate the immune system's response to infection. It is already recognised as playing a role in a number of autoimmune diseases, such as Crohn's disease (a type of inflammatory bowel disease) and psoriasis (a skin disease). Ankylosing spondylitis, Crohn's disease and psoriasis are known to often occur together, and this genetic finding goes a long way to explain why.
Professor Brown believes that the unexpected involvement of IL23R in ankylosing spondylitis provides a major step towards being able to treat the disease.
"We already know that IL23R is involved in inflammation, but no one had ever thought it was involved in ankylosing spondylitis," says Professor Brown. "A treatment for Crohn's disease that inhibits the activity of this gene is already undergoing human trials. This looks very promising as a potential treatment for ankylosing spondylitis."
Scientists have known that there is a genetic component to ankylosing spondylitis for 37 years, since the discovery of the gene HLA-B27. However, how this gene led to disease is not known. Professor Brown believes that the gene ARTS1 may hold the answer.
A protein created by the HLA-B27 gene takes fragments of pathogens and displays them on the outside of immune cells. These fragments then trigger the immune system to fight against the pathogen. ARTS1 is involved in breaking up the pathogen into "bite-size chunks" that can be displayed by HLA-B27.
"This strongly suggests that in ankylosing spondylitis, there are problems with the information that the HLA-B27 protein receives, thereby causing the disease," says Professor Brown.
Scientists believe that ankylosing spondylitis may be triggered in genetically-susceptible people by bacteria commonly found in the gut. Why this should be the case is unclear, but it is hoped that the new genetic discoveries will help answer this question.
"These findings are very exciting and show the value of exploring the genetics of disease," says Dr Mark Walport, Director of the Wellcome Trust. "It usually takes many years between genetic discoveries and new treatments for disease. In this case the two genes discovered to be associated with ankylosing spondylitis provide striking insights into the mechanisms of the disease and offer a possible new pathway for treatment."
The study is a collaboration between the Wellcome Trust Case Control Consortium and the Australo-Anglo-American Spondylitis Consortium funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
"These genetic studies involve large patient samples and require expertise over a wide range of scientific specialities", says Professor Cardon. "Bringing together these two consortia was the final key that enabled these exciting discoveries."
Wellcome Trust
Ankylosing Spondylitis Current Events and Ankylosing Spondylitis News RSSCV risk management should be mandatory in RA and other types of inflammatory rheumatic disease
Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients should undergo compulsory cardiovascular (CV) risk management and existing CV risk calculators should be adapted to the increased CV risk in inflammatory rheumatic disease patients.
New findings show Enbrel significantly reduced levels of C-reactive protein
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment.
Phase 3 data show golimumab improved psoriatic arthritis symptoms
Patients with active psoriatic arthritis receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) experienced significant and sustained improvements in the joint and skin manifestations of the disease.
Golimumab significantly reduced signs and symptoms of ankylosing spondylitis
More than half of patients receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) 50 mg and 100 mg experienced significant and sustained improvements in the signs and symptoms of active ankylosing spondylitis, according to Phase 3 study results presented at the American College of Rheumatology (ACR) annual meeting.
Study reveals 2 genes linked to disabling arthritis
An international team of researchers led by a Fred Hutchinson Cancer Research Center geneticist has discovered two genes linked to a disabling form of arthritis called ankylosing spondylitis, a painful and progressive disease in which some or all of the spine's vertebrae fuse together.
UT Rheumatologists Discover Two Genes
Work done in part by researchers at The University of Texas Medical School at Houston has led to the discovery of two genes that cause ankylosing spondylitis, an inflammatory and potentially disabling disease. The findings are published in the Oct. 21 online edition of Nature Genetics, a journal that emphasizes research on the genetic basis for common and complex diseases.
Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Clinical data presented today at the annual meeting of the American College of Gastroenterology (ACG) show that REMICADE significantly reduces the incidence of colectomy surgeries for patients with moderately to severely active ulcerative colitis (UC).
Largest ever study of genetics of common diseases published today
The Wellcome Trust Case Control Consortium, the largest ever study of the genetics behind common diseases such as diabetes, rheumatoid arthritis and coronary heart disease, today publishes its results in the journals Nature and Nature Genetics.
Monoclonal antibody reduces exacerbations in asthmatics
Patients with symptomatic moderate asthma who were treated with anti-tumor necrosis factor alpha, an anti-inflammatory monoclonal antibody, experienced significantly fewer disease exacerbations than individuals taking a placebo.
NICE gives backing for the use of advanced biological therapies to treat severe psoriasis
The UK National Institute for Health and Clinical Excellence (NICE) has today issued guidance for the use of the targeted biological therapies, Enbrel® (etanercept) and Raptiva® (efalizumab), to treat adult patients with severe plaque psoriasis.
More Ankylosing Spondylitis Current Events and Ankylosing Spondylitis News Articles
 | Ankylosing Spondylitis: The Facts (The Facts Series) by Muhammad Asim Khan Ankylosing spondilitis is a chronic form of arthritis known to affect around 1 in 200 people(over 1 million sufferers in the USA alone). Ankylosing spondilitis: the facts is the first mass market book to be published on this important disease written by someone who is not only a leading expert on AS, but is affected by it... |
 | Ankylosing Spondylitis (Fast Facts) by Maxime Dougados, Desiree, M.D. van der Heijde Ankylosing Spondylitis is an insidious disease that is often difficult to diagnose in the early stages but can cause progressive and sometimes severe disability. This handbook, written by international experts, clearly describes the features of ankylosing spondylitis and emphasizes the importance of accurate assessment. It then discusses the evidence regarding the evidence regarding the efficiacy... |
| Ankylosing Spondylitis (Oxford American Respiratory Library) by Muhammad Asim Khan Ankylosing Spondylitis (AS) and related diseases called spondyloarthropathies (SpA) are the second most common form of chronic inflammatory arthritis after Rheumatoid Arthritis (RA). Unfortunately, most patients with AS and SpA are either never diagnosed, or they are inadequately treated. The current mean delay in the diagnosis of AS ranges from 5 to 10 years, and the presenting clinical... | |
 | 21st Century Complete Medical Guide to Ankylosing Spondylitis, Authoritative CDC, NIH, and FDA Documents, Clinical References, and Practical Information for Patients and Physicians (CD-ROM) by PM Medical Health News This up-to-date electronic book on CD-ROM provides the best collection available anywhere of official Federal government information and documents on the subject of Ankylosing Spondylitis (AS). This CD-ROM uses next-generation search technology that allows complete indexing and makes all files on the disc fully searchable. For patients, practical information is provided in clearly written patient... |
 | Ankylosing Spondylitis and the Spondyloarthropathies: A Companion to Rheumatology 3E by Michael H. Weisman, John D. Reveille, Desiree van der Heijde Developed as a companion text to the 3rd Edition of the heralded Rheumatology, by Hochberg et al., this state-of-the-art reference presents today's understanding of the spondylarthropathies. You'll find thorough examinations of the innovative, new treatments that challenge older concepts of treatment and management of the disease. Noted experts in the field also present the latest concepts in... |
 | Ankylosing Spondylitis: Diagnosis and Management The first and only interdisciplinary guide dedicated to the subject, this reference leads readers through the pathogenic, genetic, clinical, and biomechanical aspects of ankylosing spondylitis (AS). It also addresses issues related to outcomes assessment, medical treatment, surgical complications, disease management, and genetics. Detailing current treatment options and clinical essentials, this... |
 | Ankylosing Spondylitis Medical Guide by Qontro Medical Guides The Ankylosing Spondylitis Medical Guide is a publication which has been designed to better help readers understand Ankylosing Spondylitis. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Ankylosing Spondylitis. The Ankylosing Spondylitis Medical Guide is highly recommended for those... |
 | Ankylosing Spondylitis - A Bibliography and Dictionary for Physicians, Patients, and Genome Researchers by Philip M. Parker In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.... |
| Ankylosing spondylitis: Discussions in patient management by Andrei Calin | |
| ANKYLOSING SPONDYLITIS: A PORTRAIT SURVEY. (SIGNED). |
| © 2009 BrightSurf.com |